Scinai Immunotherapeutics (NASDAQ: SCNI) announced that Chief Executive Officer Amir Reichman will co-lead a Manufacturers Association of Israel–organized roundtable discussion titled “Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale” during HealthIL Week 2026. The session, scheduled for Jan. 19, 2026, at Expo Tel Aviv, will focus on Israel’s biopharma development and manufacturing ecosystem, including early-stage development, CMC activities, and clinical manufacturing, as well as readiness for later-stage and commercial manufacturing. The roundtable is expected to bring together representatives from government agencies, biopharma manufacturers, CDMOs, multinational pharmaceutical companies, biotech firms, and investors to examine current capabilities, structural gaps, and collaboration models shaping the sector’s future.
To view the full press release, visit https://ibn.fm/rxzaD
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units:
- Scinai Bioservices, a boutique CDMO providing analytical method development, process development, and clinical cGMP manufacturing services for biotech clients worldwide.
- Scinai R&D, focused on developing innovative I&I therapeutics based on NanoAbs (VHH antibody fragments) with unique physicochemical properties suitable for advanced mono- and multi-specific antibody formats.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN